Osimertinib Vs Amivantamab Combos in EGFR/TP53-Mutated NSCLC
A Satellite Session hosted in Seattle, WA, focused on various treatment options that would best benefit a patient with EFGR and TP53 mutated non–small cell lung cancer. The panel mainly focused on osimertinib (Tagrisso) or Lazertinib (Lazcluze) plus …